ClinicalTrials.gg
CompletedNCT06542614Updated Jan 30, 2026

Treatment of Moderate to Severe Plaque Psoriasis

A Phase 2 interventional study of TQH3906 capsules and Placebo of TQH3906 capsules in Plaque Psoriasis, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Completed at 35 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
209
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Enrollment
79th of 182
209 · median 171
Started
2024
with 24 others
Phase 2
42 of 206
11 open now
Registered
137th of 206
by date
Lead sponsor
5 of 206
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Among the 206 studies in Psoriasis with a site in China, this one is the 79th largest by enrollment of the 182 interventional ones that give a count, is one of 25 that started in 2024, is one of 42 in phase 2, and was the 137th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

To assess the efficacy and safety of TQH3906 in subjects with moderate to severe plaque psoriasis, as well as the PK and PD characteristics of multiple doses

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be 18-70 years old (both 18 and 70 years old), regardless of gender;
  • Clinically diagnosed with stable moderate to severe plaque psoriasis with a history ≥ 6 months (from randomization), and no morphological changes in skin lesions or significant disease outbreaks as assessed by the investigator;
  • Appropriate for systemic therapy or phototherapy as judged by the investigator;
  • At screening and baseline, the PASI score was ≥ 12 points, the BSA ≥ 10%, and the sPGA ≥ 3 points ;
  • Have a full understanding of this study, voluntarily participate in the trial, and have signed a written form;
  • Subjects (including partners) are willing to voluntarily use appropriate and effective measures from screening to 3 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Pregnant and lactating females;
  • Have other forms of psoriasis other than plaque psoriasis (e.g., guttate psoriasis, generalized pustular psoriasis, erythrodermic psoriasis, arthropathic psoriasis);
  • Presence of serovirological abnormalities during the screening period:

    1. Active hepatitis, or surface antigen (HBsAg) positive, or hepatitis B core antibody (HBcA positive and Hepatitis B virus (HBV) DNA positive, or virus (HCV) antibody positive and HCV-RNA positive;
    2. Positive for antibody during the screening period, or have a history of HIV infection in the past;
    3. Positive Treponema pallidum antibody and positive non-Treponema pallidum serum test (RPR or TRUST) during the screening period;
  • Have a history of active tuberculosis during the screening period or before, or have latent tuberculosis infection found at screening (refers to T-SPOT positive without clinical manifestations). (Note: Patients with latent tuberculosis infection can be re-screened 1 month after starting prophylaxis according to the guidelines, and in order to continue to participate in the study, patients must agree to continue to complete the prophylactic regimen during the study, but rifampicin treatment should be avoided.) ;
  • Has a history of severe herpes zoster or herpes simplex infection, including but not limited to herpetic encephalitis, disseminated herpes simplex, generalized herpes zoster;
  • History of severe bacterial, fungal or viral infection within 2 months prior to randomization, requiring hospitalization for intravenous antibiotics or antiviral drug treatment;
  • within 4 weeks prior to randomization or planned live vaccine during the study;
  • infection, including but not limited to upper respiratory tract infection, lower respiratory tract infection, herpes simplex, herpes zoster, during the screening period, and requiring antibiotic or antiviral medication treatment;
  • Has any significant illness or unstable clinical condition (such as renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, psychiatric, neurological, immune, or locally active infectious/infectious disease) that is judged by the investigator to be unsuitable for participation in this study.
  • Abnormal laboratory tests during the screening period:

    1. (ALT) or aspartate aminotransferase (AST) ≥ 3 times (ULN);
    2. \<90g/L;
    3. White blood cell count\< 3.0×109/L;
    4. \<1.0×109/L;
    5. Lymphocyte count\<0.5×109/L;
    6. count \< 100×109/L;
    7. Total >2 times ULN;
    8. Other significant laboratory test abnormalities that, in the opinion of the investigator, the subject is not suitable for participation in this study.
  • History of malignant tumors (including carcinoma in situ) and lymphoproliferative disorders within 5 years prior to randomization;
  • Those who have received at least 6 consecutive months of anti-IL-12, IL-17, IL23 monoclonal antibody drugs (such as ustekin, secukziu, ichizzo, gusechiu, etc.) at the approved dose but have poor clinical response (defined as not achieving PASI 50 during treatment);
  • Receipt of any other marketed or biologic agent within 3 months or 5 half-lives (whichever is longer) prior to randomization;
  • Receipt of any other investigational drug in 1 month or 5 half-lives (whichever is longer) prior to randomization;
  • Those who have undergone surgical surgery within 4 weeks prior to randomization, or who plan to undergo surgical procedures during the study;
  • Those who have lost blood or donated more than 400 mL of blood within 4 weeks prior to randomization;
  • Receipt of immunoglobulin or blood products within 4 weeks prior to randomization;
  • Systemic treatment drugs or for psoriasis within 4 weeks prior to randomization, including but not limited to retinoids, , methotrexate, cyclosporine, azathioprine, Janus kinase (JAK) inhibitors, etc;
  • Use of strong CYP450 inducers (such as rifampicin, phenobarbital, carbamazepine, phenytoin, etc.) within 4 weeks prior to randomization;
  • Received topical or systemic phototherapy within 4 weeks prior to randomization, including but not limited to Narrow-band ultraviolet B (NB-UVB), photochemotherapy (PUVA), 308nm excimer light;
  • Use of topical drugs that may affect the severity of skin lesions in psoriasis within 2 weeks prior to randomization, including but not limited to glucocorticoids, urea, >3% salicylic acid, α or β hydroxy acids, retinoids, vitamin D3 analogues, calcineurin inhibitors, Phosphodiesterase-4 (PDE-4) inhibitors, etc. (Note: Mild emollients (without active substances such as urea, salicylic acid, α, or β hydroxy acids) are allowed to be used at all sites, but should not be used within 24 hours prior to each study visit);
  • Potential difficulty in blood collection, with a history of fainting needle and blood sickness;
  • Allergy to any of the known ingredients of the TQH3906, or any previous history of severe drug allergies.
  • Those with a history of substance abuse;
  • Has any other reasonable medical, psychiatric, or social reason that, in the opinion of the investigator, precludes participation in this study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
209 participants (actual)

Study arms

  • Experimental
    TQH3906 capsules

    TQH3906 capsules are administered orally at the same time (±2 hours) on an empty stomach every day for 12 weeks starting from Day 1.

    Drug: TQH3906 capsules

  • Placebo comparator
    Placebo of TQH3906 capsules

    TQH3906 capsules placebo: TQH3906 capsules placebo administered orally once daily for 12 weeks at the same time (±2 hours) on an empty stomach starting from Day 1.

    Drug: Placebo of TQH3906 capsules

Interventions

  • To assess the efficacy and safety of TQH3906 in subjects with moderate to severe plaque psoriasis.

  • DrugPlacebo of TQH3906 capsules

    Placebo without drug substance.

06

What researchers measure

Primary outcomes

  1. Proportion of patients achieving Psoriasis Area and Severity Index (PASI) 75 at week 12

    Achieve a PASI 75 ratio

    Time frame: Up to week 12

Secondary outcomes

  1. Proportion of patients achieving Static Physician's Global Assessment (sPGA) 0/1 at week 12

    It is used to observe the proportion of patients with 0 or 1

    Time frame: Up to week 12

  2. Proportion of patients achieving PASI 50 at week 12

    Observed proportion of patients achieving PASI 50 at week 12

    Time frame: Up to week 12

  3. Proportion of patients achieving PASI 90 at week 12

    Observed proportion of patients achieving PASI 90 at week 12

    Time frame: Up to week 12

  4. Proportion of patients achieving PASI 100 at week 12

    Observed proportion of patients achieving PASI 100 at week 12

    Time frame: Up to week 12

  5. Body Surface Area (BSA) score

    To observe the degree of change from baseline in BSA score at week 12

    Time frame: Up to week 12

  6. Dermatology Life Quality Index (DLQI) score

    To observe the degree of change from baseline in DLQI score at week 12

    Time frame: Up to week 12

  7. Incidence of abnormal laboratory test markers

    The proportion of patients with abnormal laboratory examination indicators, including blood routine and liver function, mainly includes blood routine, liver function, etc.

    Time frame: From randomization to 4 weeks after the last dose

  8. Adverse event (AE)

    Proportion of patients with adverse events, defined by Common Terminology Criteria for Adverse Events (CTCAE) 5.0.

    Time frame: From randomization to 4 weeks after the last dose

  9. Serious Adverse Events (SAEs)

    Proportion of patients with serious adverse events, defined by Common Terminology Criteria for Adverse Events (CTCAE) 5.0.

    Time frame: From randomization to 4 weeks after the last dose.

  10. Tmax, ss

    Refers to the time when the blood concentration reaches its peak after a single dose. At this point in time, the blood concentration is the highest.

    Time frame: Within 1 hour before Day1, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours, Day 15, Day 29, Day 57, Day 85 within 1 hour before administration, 1,1.5, 2, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours after Day 85

  11. Cmax, ss

    The steady-state concentration of the drug after multiple doses was investigated. Within 1 hour before Day1, 1 hour, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours, Day15, Day29, Day57, Day85 within 1 hour before administration, and 1 hour, 1.5, 2, 2.5, 3, 4, 6, 8,12, 24, 48, 72 hours after Day85.

    Time frame: Within 1 hour before Day1, 1 hour, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours, Day15, Day29, Day57, Day85 within 1 hour before administration, and 1 hour, 1.5, 2, 2.5, 3, 4, 6, 8,12, 24, 48, 72 hours after Day85

  12. Cmin, ss

    The lowest concentration from the initial moment after administration to the lowest concentration before the next dose when multiple doses reach steady state. This index is a common indicator to reflect the level of drug accumulation, and is closely related to the drug dose, dosing interval and drug elimination rate.

    Time frame: Within 1 hour before Day1, 1 hour, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours, Day15, Day29, Day57, Day85 within 1 hour before administration, and 1 hour, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72 hours after Day85

  13. Area under the plasma concentration-time curve (AUC) 0-τ

    When multiple administrations reach steady state, the area under the plasma concentration curve of each dosing interval is equal to the area under the plasma concentration curve from the time after administration to infinity.

    Time frame: Within 1 hour before Day1 administration, 1 hour, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours, Day15, Day29, Day57, Day85 within 1 hour before administration, and 1 hour, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72 hours after Day85

  14. Rac

    The ratio of the dose required to be given in one dose to the total dose required to be given in divided doses.

    Time frame: Within 1 hour before Day1 administration, 1 hour, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours, Day15, Day29, Day57, Day85 within 1 hour before administration, and 1 hour, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72 hours after Day85

  15. Interleukin-17A (IL-17A) in serum

    Change from baseline in serum IL-17A

    Time frame: Within 1 hour before Day1 administration, Day15, Day29, Day85

  16. Interleukin 19 (IL-19) in serum

    Change from baseline in serum IL-19

    Time frame: Within 1 hour before Day1 administration, Day15, Day29, Day85

  17. β defensin in serum

    Change from baseline in serum β defensin

    Time frame: Within 1 hour before Day1 administration, Day15, Day29, Day85

07

Study locations

35 sites
  • The Second Affiliated Hospital of Wannan Medical College
    Wuhu, Anhui 241000, China
  • Beijing Tongren Hospital, Capital Medical University
    Beijing, Beijing Municipality 100730, China
  • The first affiliated hospital of chongqing medical university
    Chongqing, Chongqing Municipality 400042, China
  • Dermatology Hospital of Southern Medical University
    Guangzhou, Guangdong 510091, China
  • Liuzhou People'S Hospital
    Liuzhou, Guangxi 545006, China
  • Shijiazhuang Hospital of Traditional Chinese Medicine
    Shijiazhuang, Hebei 50000, China
  • The Second Hospital of HeBei Medical University
    Shijiazhuang, Hebei 50000, China
  • The Second Affiliated Hospital Of Xingtai Medical Colledge
    Xingtai, Hebei 054002, China
  • Heilongjiang Provincial Hospital
    Harbin, Heilongjiang 150036, China
  • The Second Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan 471000, China
  • Nanyang First People'S Hospital
    Nanyang, Henan 473010, China
  • Shiyan Renmin Hospital
    Shiyan, Hubei 442000, China
  • Wuhan First Hospital
    Wuhan, Hubei 430033, China
  • The First People's Hospital of Changde
    Changde, Hunan 415100, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410000, China
  • The First Affiliated Hospital of Baotou Medical College
    Baotou, Inner Mongolia 014000, China
  • Hospital of Dermatology, Chinese Academy of Medical Sciences
    Nanjing, Jiangsu 210000, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
  • Yancheng First People's Hospital
    Yancheng, Jiangsu 224006, China
  • The First Bethune Hospital of Jilin University
    Changchun, Jilin 130031, China
  • Meihekou Central Hospital
    Meihekou, Jilin 135000, China
  • Genertec Liaoyou Gem Flower Hospital
    Panjin, Liaoning 124000, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning 110000, China
  • The first hospital of china medical university
    Shenyang, Liaoning 110001, China
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710000, China
  • Shandong First Medical University Affiliated Dermatology Hospital
    Jinan, Shandong 250022, China
  • Shandong University Qilu Hospital
    Jinan, Shandong 250063, China
  • Qingdao Municipal hospital (group)
    Qingdao, Shandong 266011, China
  • Qingdao Traditional Chinese Medicine Hospital
    Qingdao, Shandong 266033, China
  • Shanghai JiaoTong University of medicine Ruijin Hospital
    Shanghai, Shanghai Municipality 20025, China
  • Shanxi Provincial People's Hospital
    Taiyuan, Shanxi 030012, China
  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
    Tianjin, Tianjin Municipality 300120, China
  • Xinjiang Uygur Autonomous Region People's Hospital
    Ürümqi, Xinjiang 830001, China
  • Affiliated Hangzhou First People'S Hospital,School of Medicine, Westlake University
    Hangzhou, Zhejiang 310003, China
  • The Second Affiliated Hospital Zhejiang University School Of Medicine
    Hangzhou, Zhejiang 310009, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Nov 2025, 14 months.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 14 months is above that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2024
First posted
Aug 7, 2024
StartActual
Aug 27, 2024
Primary completionActual
Nov 3, 2025
CompletionActual
Dec 6, 2025
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06542614
Responsible party
Sponsor
First posted
Aug 7, 2024
Start date
Aug 27, 2024
Primary completion
Nov 3, 2025
Completion
Dec 6, 2025
Last update
Jan 30, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQH3906

Start the discussion